Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

• ClinicalTrials.gov Identifier: NCT01701037
• Recruitment Status: Terminated
• First Posted: October 4, 2012
• Results First Posted: June 23, 2017
• Last Update Posted: June 23, 2017
• Sponsor: Vanderbilt-Ingram Cancer Center
• Collaborators: National Cancer Institute (NCI); National Comprehensive Cancer Network
• Information provided by (Responsible Party): Mark Kelley, MD, Vanderbilt-Ingram Cancer Center

Study Description

Brief Summary:

This phase II trial studies how well giving dabrafenib alone and in combination with trametinib before surgery works in treating patients with advanced melanoma that can be removed by surgery. Studying samples of tumor tissue in the laboratory from patients receiving dabrafenib and trametinib may help doctors learn more about the effects of these drugs on cells and help identify biomarkers that determine which patients will respond to these drugs best.

Condition or disease	Intervention/treatment	Phase
Recurrent Melanoma; Stage IIB Melanoma (Locally Advanced); Stage IIC Melanoma (Locally Advanced); Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma (Limited, Resectable)	Drug: dabrafenib; Drug: trametinib; Other: laboratory biomarker analysis	Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To identify markers of intrinsic resistance to v-Raf murine sarcoma viral oncogene homolog B1 (B-RAF) targeted therapy in B-RAF mutation-positive melanoma.

SECONDARY OBJECTIVES:

I. To determine if intrinsic resistance can be reversed by mitogen activated protein kinase (MEK) targeted therapy and to identify biomarkers that correlate with this response.

II. To evaluate the feasibility of pre-surgical targeted therapy and serial tumor biopsies in patients with advanced, operable melanoma to determine if this model can be used to evaluate novel combinations of molecular targeted therapy in the future.

TERTIARY OBJECTIVES:

I. To determine if pre-surgical B-RAF and MEK targeted therapy is active and well tolerated in patients with advanced, operable melanoma. These findings may be used to support clinical trials in un-resectable, B-RAF mutation-positive melanoma.

OUTLINE:

Patients receive dabrafenib orally (PO) twice daily (BID) on days 1-28 adding trametinib on days 15-28 followed by surgery on days 28-30. Treatment continues until the day prior to surgery in the absence of unacceptable toxicity.

After completion of study treatment, patients are followed up for 3 months.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 13 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: Biomarkers of Response and Resistance to Sequential B-RAF and MEK Targeted Therapy in a Pre-Surgical Model of Advanced, Operable Melanoma
• Study Start Date: January 2013
• Actual Primary Completion Date: February 2015
• Actual Study Completion Date: April 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Dabrafenib and Trametinib; Patients receive dabrafenib PO BID on days 1-28 adding trametinib on days 15-28 followed by surgery on days 28-30. Treatment continues in the absence of unacceptable toxicity.	Drug: dabrafenib; 150 mg given PO; Other Names: BRAF inhibitor GSK2118436; GSK2118436; Drug: trametinib; 2 mg given PO; Other Name: GSK1120212; Other: laboratory biomarker analysis; Correlative studies

Outcome Measures

Primary Outcome Measures :

1. Clinical Tumor Response Rate (Response is Based on Greater Than 30% Reduction From Baseline in Tumor Volume by RECIST Criteria) at Day 14. [ Time Frame: day 14 ]
   Tumor response is defined as greater than 30% reduction from baseline in tumor volume by RECIST criteria. To determine whether a patient is responded at day 14, the patient must have the tumor volume evaluated at both baseline and day 14. The tumor response rate is calculated as the proportion of patients responded among all evaluated patients.

Secondary Outcome Measures :

1. Change in Tumor Volume Reduction in Participants With Intrinsic Resistance to B-RAF Targeted Therapy From Day 14 to Day 28. [ Time Frame: Day 14 and day 28 ]
   Tumor volume reduction is calculated as the tumor volume change relative to the baseline measurement (percent). Change in tumor volume reduction from day 14 to day 28 is calculated as the difference of tumor volume reduction at day 28 and day 14. The median and Inter-Quartile Range are reported.
2. Number of Patients With Worst Grade Toxicities by Grade According to National Cancer Institute (NCI) CTCAE Version 4.0 [ Time Frame: Up to 3 months ]

   The intensity of the adverse event will be graded according to Version 4.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events (June 14, 2010):

   Grade 1 - Mild Grade 2 - Moderate Grade 3 - Severe or medically significant Grade 4 - Life-threatening Grade 5 - Death related to adverse event

3. Investigational Agent Taken [ Time Frame: Up to 3 months ]
   Median number of pills taken
4. Percent of Patients Completing Second and Third (Surgical) Biopsies [ Time Frame: Up to 3 months ]
   Biopsies will be assessed whether or not tissue is acquired at specified time points. Tissue is obtained through core, punch, incisional or excisional biopsy or surgical resection, based upon the clinical situation. Standard operating procedures for biopsies, sample preparation and analysis have been defined.
5. Percentage of Biopsies With Adequate Tissue for Biomarker Analysis [ Time Frame: Up to 3 months ]
   Measured by the percent of tumor necrosis on hematoxylin and eosin stains; RNA gel electrophoresis, percent of adequate tissue for immunohistochemical stains in tissue microarray and cyTOF analysis.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 90 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Signed written informed consent

• Patients with locally-or regionally advanced melanoma being considered for resection of the lesion(s) for local-regional control and potential cure

  • Patients with limited, resectable metastatic disease (three or fewer lesions) are eligible if surgical resection is considered to be the best therapeutic option
  • Patients with AJCC clinical stage IIb-IV disease at initial diagnosis, or patients with melanoma of any stage with advanced local or regional recurrence, with or without limited resectable metastatic disease, would be eligible

• B-RAF V-600 mutation positive by snapshot molecular analysis

  • Individuals with B-RAF V-600 mutations other than V600E are eligible
• Measurable disease, i.e. presenting with at least one measurable lesion per Response Evaluation Criteria in Solid tumors (RECIST) 1.1
• All prior treatment related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) (Version 4.0) =< Grade 1 at the time of enrollment

• Adequate baseline organ function defined by the criteria below:

  • Absolute Neutrophil Count (ANC) >= 1.5 X 10^9/L
  • Platelet Count >= 60 X 10^9/L
  • Hemoglobin >= 9 g/dl
  • Creatinine =< 2 mg/dl
  • Aspartate aminotransferase (AST) =< 100 U/L
  • Alanine aminotransferase (ALT) =< 100 U/L
  • Alkaline Phosphatase =< 380 U/L
  • Total Bilirubin =< 2.0 mg/dl
• Women of childbearing potential must have a negative serum pregnancy test within 14 days of first dose of study treatment and agree to use effective contraception during the study and for 7 days following the last dose of study treatment
• Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from 1 day prior to administration of the first dose of study treatment until 7 days after the last dose of study treatment

Exclusion Criteria:

• ECOG Performance Status > 2
• Lactating female
• Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures
• Any serious medical condition that would render the patient unable to undergo surgical resection or would limit life expectancy to less than 1 year
• Any prohibited medication
• Administration of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment
• A known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK-2118436 (dabrafenib) or GSK-1120212 (trametinib) or excipient that contraindicates their participation

• Patients with a history of severe cardiovascular disease as defined:

  • Symptomatic or uncontrolled cardiac arrhythmias
  • Treatment refractory hypertension, defined as a systolic blood pressure > 160mm Hg and/or diastolic > 100 mmHg which cannot be controlled by antihypertensive therapy.
  • Current ≥ NYHA Class II congestive heart failure
  • History of myocardial infarction or unstable angina within 6 months prior to study entry.
  • History of stroke or TIA within 6 months prior to study entry
  • QTc ≥ 480 msec
  • Cardiac valvular disease ≥ grade 2.
• Patients with a history of interstitial lung disease or interstitial pneumonitis
• A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection.
• History of another active malignancy within the past 5 years, or any malignancy with a confirmed activating RAS mutation. Please note that prospective RAS mutation testing is not required, however, if results of previous RAS testing are known, they must be used in assessing eligibility. Subjects with a history of completely resected non-melanoma skin cancer are eligible.
• A history or current evidence/risk of retinal vein occlusion (RVO) or CSR including:
• a. Presence of predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled diabetes mellitus, or a history of hyperviscosity or hypercoagulability syndromes); or

• b. Visible retinal pathology as assessed by ophthalmic examination that is considered a risk factor for RVO or CSR such as:

  • i. Evidence of new optic disc cupping;
  • ii. Evidence of new visual field defects on automated perimetry;
  • iii. Intraocular pressure >21 mmHg as measured by tonography.

Contacts and Locations

Locations

United States, Tennessee

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, United States, 37232-6838

Sponsors and Collaborators

Vanderbilt-Ingram Cancer Center

National Cancer Institute (NCI)

National Comprehensive Cancer Network

Investigators

• Principal Investigator: Mark Kelley; Vanderbilt-Ingram Cancer Center

More Information

Additional Information:

Vanderbilt-Ingram Cancer Center, Find a Clinical Trial 

Publications of Results:

Johnson AS, Crandall H, Dahlman K, Kelley MC. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma. J Am Coll Surg. 2015 Apr;220(4):581-93.e1. doi: 10.1016/j.jamcollsurg.2014.12.057. Epub 2015 Jan 30.

• Responsible Party: Mark Kelley, MD, Chief, Division of Surgical Oncology and Endocrine Surgery; Associate Professor of Surgery; Surgical Oncologist, Vanderbilt-Ingram Cancer Center
• ClinicalTrials.gov Identifier: NCT01701037
• Other Study ID Numbers: VICC MEL 1263; NCI-2012-01699 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
• First Posted: October 4, 2012
• Results First Posted: June 23, 2017
• Last Update Posted: June 23, 2017
• Last Verified: June 2017

Keywords provided by Mark Kelley, MD, Vanderbilt-Ingram Cancer Center:

Melanoma, B-RAF, biomarkers, targeted therapy, resistance

Additional relevant MeSH terms:

Melanoma; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Trametinib; Dabrafenib; Antineoplastic Agents; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action